comparemela.com

Page 2 - Yong Cang News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Degron Therapeutics Raises $22M Series A Financing to Accelerate Growth and Expand Molecular-Glue-Based Targeted Protein Degradation Drug Discovery Platform

/PRNewswire/ Degron Therapeutics ("Degron"), a biotechnology company developing a new class of small-molecule medicines that target previously undruggable.

Jing yuLily zouYong cangShanghaitech universityDyee capitalBaidu ventureNeux capitalYuanbio ventureDegron therapeuticsMed fine capital

Degron Raises $22 Million to Advance Molecular-Glue-Based Protein Degradation Platform

Degron Raises $22 Million to Advance Molecular-Glue-Based Protein Degradation Platform
globalgenes.org - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from globalgenes.org Daily Mail and Mail on Sunday newspapers.

San diegoUnited statesJing yuLily zouYong cangShanghaitech universityFine capitalDyee capitalBaidu ventureNeux capitalYuanbio ventureDegron therapeuticsMed fine capital

vimarsana © 2020. All Rights Reserved.